Skip to main content

Table 3 Antimicrobial-resistance profiles of Listeria isolates from the four areas (n = 59)

From: Antimicrobial susceptibility, multilocus sequence typing, and virulence of listeria isolated from a slaughterhouse in Jiangsu, China

Source and no. of resistant strains (%)
Antibitocs
(ug/ml)
Slaughter area
n = 7
Cutting and deboning room
n = 9
Visceral area
n = 23
Meat cooling and refrigeration area
n = 20
Total
GEN R ≥ 16 0 (0.00%) 0 (0.00%) L. welshimeri (1) (4.35%) L. welshimeri (1) (5.00%) 2 (3.39%)
  I = 8 0 (0.00%) 0 (0.00%) L.m (1) (4.35%) 0 (0.00%) 1 (1.69%)
  S ≤ 4 L. innocua (1)
L. m(6) (100.00%)
L. innocua (2)
L. m (7) (100.00%)
L. innocua (1) L. welshimeri (9)
L. m (11) (91.30%)
L. innocua (3) L. welshimeri (3)
L. m(13) (95.00%)
56 (94.92%)
CAZ R ≥ 32 L. innocua (1)
L. m(6) (100.00%)
L. innocua (2)
L. m (7) (100.00%)
L. innocua (1) L. welshimeri(10) L. m (11) (95.65%) L. innocua (3) L. welshimeri (4)
L. m (13) (100.00%)
58 (98.31%)
  I = 16 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
  S ≤ 8 0 (0.00%) 0 (0.00%) L. welshimeri (1) (4.35%) 0 (0.00%) 1 (1.70%)
AMP R ≥ 32 L. m (1)
(14.29%)
0 (0.00%) 0 (0.00%) 0 (0.00%) 1 (1.69%)
  I = 16 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
  S ≤ 8 L. innocua (1)
L. m (5) (85.71%)
L.innocua (2)
L. m (7) (100.00%)
L. innocua (1) L. welshimeri (11) L. m (11) (100.00%) L. innocua (3) L. welshimeri (4)
L. m (13) (100.00%)
58 (98.31%)
CIP R ≥ 4 L. innocua (1)
L. m (6) (100.00%)
L. innocua (2)
L. m (6) (88.89%)
L. innocua (1) L. welshimeri(10) L. m (11) (95.65%) L. innocua (3) L. welshimeri (4)
L. m (13) (100.00%)
57 (96.61%)
  I = 2 0 (0.00%) 0 (0.0%) L. welshimeri (1) (4.35%) 0 (0.0%) 1 (1.69%)
  S ≤ 1 0 (0.00%) L. m (1) (11.11%) 0 (0.00%) 0 (0.00%) 1 (1.69%)
TET R ≥ 16 L. m (1) (14.29%) L. innocua (2)
L. m (1) (33.33%)
L. innocua (1) L. welshimeri (2)
L. m (1) (17.39%)
L. innocua (1)
L. m (1) (10.00%)
10 (16.95%)
  I = 8 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
  S ≤ 4 L. innocua (1)
L. m (5) (85.71%)
L. m (6) (72.7%) L. welshimeri (9)
L. m (10) (82.61%)
L. innocua (2) L. welshimeri (4)
L. m (12) (90.00%)
49 (83.05%)
ERY R ≥ 8 0 (0.00%) 0 (0.00%) L. welshimeri (1)
L. m (1) (8.70%)
L. welshimeri (1)
L. m (1) (10.00%)
4 (6.78%)
  I = 1–4 L. m (2) (28.57%) L. innocua (2)
L. m (4) (66.67%)
L. innocua (1) L. welshimeri (7)
L. m (3) (47.83%)
L. welshimeri (2) L. m (8)
(50.00%)
29 (49.15%)
  S ≤ 0.5 L. innocua (1)
L. m (4) (71.43%)
L. m (3) (33.33%) L. welshimeri(3)
L. m (7) (43.48%)
L. innocua (3) L. welshimeri(1)
L. m (4) (40.00%)
26 (44.07%)
LIN R ≥ 4 L. innocua (1) L. m (5)
(85.71%)
L. innocua (2)
L. m (7) (100.00%)
L. innocua (1) L. welshimeri (9) L. m (11) (91.30%) L. innocua (3) L. welshimeri (4)
L. m (12) (95.00%)
55 (93.22%)
  I = 1–2 L. m (1) (14.29%) 0 (0.00%) L. welshimeri (2) (8.70%) L. m (1) (5.00%) 4 (6.78%)
  S - 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
VAN R ≥ 32 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
  I = 8–16 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
  S ≤ 4 L. innocua (1)
L. m (6) (100.00%)
L. innocua (2)
L. m (7) (100.00%)
L. innocua (1) L. welshimeri (11) L. m (11) (100.00%) L. innocua (3) L. welshimeri (4)
L. m (13) (100.00%)
59 (100.00%)
  1. GEN gentamicin, CAZ ceftazidime, AMP ampicillin, CIP ciprofloxacin, TET tetracycline, ERY erythromycin, LIN lincomycin, VAN vancomycin